Your browser doesn't support javascript.
loading
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii.
Hoover, Jennifer L; Lewandowski, Thomas F; Mininger, Cindy L; Singley, Christine M; Sucoloski, Scott; Rittenhouse, Stephen.
Afiliação
  • Hoover JL; Antibacterial Discovery Performance Unit, GlaxoSmithKline; Jennifer.L.Hoover@gsk.com.
  • Lewandowski TF; Antibacterial Discovery Performance Unit, GlaxoSmithKline.
  • Mininger CL; Antibacterial Discovery Performance Unit, GlaxoSmithKline.
  • Singley CM; Antibacterial Discovery Performance Unit, GlaxoSmithKline.
  • Sucoloski S; Antibacterial Discovery Performance Unit, GlaxoSmithKline.
  • Rittenhouse S; Antibacterial Discovery Performance Unit, GlaxoSmithKline.
J Vis Exp ; (119)2017 01 02.
Article em En | MEDLINE | ID: mdl-28117818
Efficacy of candidate antibacterial treatments must be demonstrated in animal models of infection as part of the discovery and development process, preferably in models which mimic the intended clinical indication. A method for inducing robust lung infections in immunocompetent rats and mice is described which allows for the assessment of treatments in a model of serious pneumonia caused by S. pneumoniae, H. influenzae, P. aeruginosa, K. pneumoniae or A. baumannii. Animals are anesthetized, and an agar-based inoculum is deposited deep into the lung via nonsurgical intratracheal intubation. The resulting infection is consistent, reproducible, and stable for at least 48 h and up to 96 h for most isolates. Studies with marketed antibacterials have demonstrated good correlation between in vivo efficacy and in vitro susceptibility, and concordance between pharmacokinetic/pharmacodynamic targets determined in this model and clinically accepted targets has been observed. Although there is an initial time investment when learning the technique, it can be performed quickly and efficiently once proficiency is achieved. Benefits of the model include elimination of the neutropenic requirement, increased robustness and reproducibility, ability to study more pathogens and isolates, improved flexibility in study design and establishment of a challenging infection in an immunocompetent host.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Bacteriana / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Bacteriana / Antibacterianos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article